Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications

Overview

Journal Front Neurol

Specialty Neurology

Date 2021 Aug 2

PMID 34335440

Citations 20

Authors

Rosie Bell

Michele Vendruscolo

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease is characterised by the presence in brain tissue of aberrant inclusions known as Lewy bodies and Lewy neurites, which are deposits composed by α-synuclein and a variety of other cellular components, including in particular lipid membranes. The dysregulation of the balance between lipid homeostasis and α-synuclein homeostasis is therefore likely to be closely involved in the onset and progression of Parkinson's disease and related synucleinopathies. As our understanding of this balance is increasing, we describe recent advances in the characterisation of the role of post-translational modifications in modulating the interactions of α-synuclein with lipid membranes. We then discuss the impact of these advances on the development of novel diagnostic and therapeutic tools for synucleinopathies.

Citing Articles

Extracellular vesicles: biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases.

Wang L, Zhang X, Yang Z, Wang B, Gong H, Zhang K Transl Neurodegener. 2024; 13(1):60.

PMID: 39643909 PMC: 11622582. DOI: 10.1186/s40035-024-00453-6.

Impact of Phosphorylation on the Physiological Form of Human alpha-Synuclein in Aqueous Solution.

de Bruyn E, Dorn A, Rossetti G, Fernandez C, Outeiro T, Schulz J J Chem Inf Model. 2024; 64(21):8215-8226.

PMID: 39462994 PMC: 11558680. DOI: 10.1021/acs.jcim.4c01172.

Protein modification in neurodegenerative diseases.

Ramazi S, Dadzadi M, Darvazi M, Seddigh N, Allahverdi A MedComm (2020). 2024; 5(8):e674.

PMID: 39105197 PMC: 11298556. DOI: 10.1002/mco2.674.

Interaction between α-Synuclein and Bioactive Lipids: Neurodegeneration, Disease Biomarkers and Emerging Therapies.

Sanluca C, Spagnolo P, Mancinelli R, De Bartolo M, Fava M, Maccarrone M Metabolites. 2024; 14(7).

PMID: 39057675 PMC: 11278689. DOI: 10.3390/metabo14070352.

Interplay of α-synuclein with Lipid Membranes: Cooperative Adsorption, Membrane Remodeling and Coaggregation.

Makasewicz K, Linse S, Sparr E JACS Au. 2024; 4(4):1250-1262.

PMID: 38665673 PMC: 11040681. DOI: 10.1021/jacsau.3c00579.

References

Lashuel H, Overk C, Oueslati A, Masliah E . The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012; 14(1):38-48. PMC: 4295774. DOI: 10.1038/nrn3406. View

Danielson S, Held J, Schilling B, Oo M, Gibson B, Andersen J . Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal Chem. 2009; 81(18):7823-8. PMC: 2748813. DOI: 10.1021/ac901176t. View

Heller J, Brcina N, Dogan I, Holtbernd F, Romanzetti S, Schulz J . Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) - A systematic review on potential biomarkers for neurodegeneration. Sleep Med Rev. 2016; 34:23-33. DOI: 10.1016/j.smrv.2016.06.006. View

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

Majbour N, Vaikath N, Eusebi P, Chiasserini D, Ardah M, Varghese S . Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. Mov Disord. 2016; 31(10):1535-1542. DOI: 10.1002/mds.26754. View

Aksnes H, Drazic A, Marie M, Arnesen T . First Things First: Vital Protein Marks by N-Terminal Acetyltransferases. Trends Biochem Sci. 2016; 41(9):746-760. DOI: 10.1016/j.tibs.2016.07.005. View

Ramonet D, Daher J, Lin B, Stafa K, Kim J, Banerjee R . Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One. 2011; 6(4):e18568. PMC: 3071839. DOI: 10.1371/journal.pone.0018568. View

Mahul-Mellier A, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F . The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020; 117(9):4971-4982. PMC: 7060668. DOI: 10.1073/pnas.1913904117. View

Henderson M, Trojanowski J, Lee V . α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Neurosci Lett. 2019; 709:134316. PMC: 7014913. DOI: 10.1016/j.neulet.2019.134316. View

10.

Teixeira Dos Santos M, Bell R, da Costa A . Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting. Bioanalysis. 2016; 8(23):2497-2518. DOI: 10.4155/bio-2016-0166. View

11.

Klemann C, Martens G, Sharma M, Martens M, Isacson O, Gasser T . Integrated molecular landscape of Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:14. PMC: 5460267. DOI: 10.1038/s41531-017-0015-3. View

12.

van der Wateren I, Knowles T, Buell A, Dobson C, Galvagnion C . C-terminal truncation of α-synuclein promotes amyloid fibril amplification at physiological pH. Chem Sci. 2018; 9(25):5506-5516. PMC: 6048717. DOI: 10.1039/c8sc01109e. View

13.

Williams D, Litvan I . Parkinsonian syndromes. Continuum (Minneap Minn). 2013; 19(5 Movement Disorders):1189-212. PMC: 4234134. DOI: 10.1212/01.CON.0000436152.24038.e0. View

14.

Ma L, Yang C, Zhang X, Li Y, Wang S, Zheng L . C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(12):3714-3725. DOI: 10.1016/j.bbadis.2018.10.003. View

15.

Stewart T, Sossi V, Aasly J, Wszolek Z, Uitti R, Hasegawa K . Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun. 2015; 3:7. PMC: 4362824. DOI: 10.1186/s40478-015-0185-3. View

16.

Yeo W, Kim Y, Kabir M, Kang J, Ahsan-Ul-Bari M, Kim K . Mass spectrometric analysis of protein tyrosine nitration in aging and neurodegenerative diseases. Mass Spectrom Rev. 2014; 34(2):166-83. DOI: 10.1002/mas.21429. View

17.

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

18.

Bartesaghi S, Radi R . Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration. Redox Biol. 2017; 14:618-625. PMC: 5694970. DOI: 10.1016/j.redox.2017.09.009. View

19.

Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E . The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395(6701):451-2. DOI: 10.1038/26652. View

20.

Popova B, Kleinknecht A, Braus G . Posttranslational Modifications and Clearing of α-Synuclein Aggregates in Yeast. Biomolecules. 2015; 5(2):617-34. PMC: 4496687. DOI: 10.3390/biom5020617. View